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Antibody and DakoCytomation's Polyclonal Rabbit 
Anti-Human Glucagon: a case report
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Abstract
Introduction: This case report demonstrates that the differential immunohistochemical reactivities of Siemens' Double 
Antibody Glucagon compared to DakoCytomation's Polyclonal Rabbit Anti-Human Glucagon allow for pathologic 
distinction of enteral versus pancreatic glucagonoma.
Case presentation: A 64-year-old Caucasian man was diagnosed with a duodenal enteroglucagonoma following 
presentation with obstructive jaundice. He had a low serum glucagon level using Siemens' Double Antibody Glucagon, 
a clinical syndrome consistent with glucagon hypersecretion. A periampullary mass biopsy proved to be a 
neuroendocrine tumor, with positive immunohistochemical reactivity to DakoCytomation's Polyclonal Rabbit Anti-
Human Glucagon.
Conclusions: Differential comparison of the immunohistochemical reactivities of Siemens' Double Antibody Glucagon 
and DakoCytomation's Polyclonal Rabbit Anti-Human Glucagon discerns enteroglucagon from pancreatic glucagon.
Introduction
Pancreatic glucagonomas are rare neuroendocrine
tumors with an estimated incidence of approximately 1 in
20 million [1]. Duodenal glucagonomas are reported, but
are even rarer with an unknown true incidence [2].
Necrotizing migratory erythema (NME), glucose intoler-
ance, weight loss and anemia form a presenting constella-
tion known as the glucagonoma syndrome. Patients most
commonly present in the sixth decade of life with an even
gender distribution. Tumors usually present larger than 4
cm and are commonly associated with metastasis in over
50% of patients [3,4].
Neuroendocrine tumors are slow-growing neoplasms
[1]. Both chronic and acute pancreatitis has been associ-
ated with neuroendocrine tumors [5]. NME presents on
average 7 years before the diagnosis of glucagonoma [4,6].
Diabetes mellitus is commonly diagnosed 5 years before
the ultimate diagnosis of glucagonoma [6].
Treatment of glucagonomas depends on location, size
and lymph node involvement. Simple excision with resec-
tion of peripancreatic lymph nodes is the treatment of
choice for isolated confined lesions [7]. Periampullary,
large and metastatic tumors require more extensive
resection [7]. Surgical debulking has demonstrated
decreased morbidity and increased survival [3]. For
advanced lesions, octreotide is the treatment of choice for
symptomatic control [7].
"Enteroglucagon" applies to a group of proglucagon
peptide cleavage fragments. The proglucagon moiety
forms the precursor molecule for both pancreatic and
enteral glucagon. Differential proteolytic processing
occurs in these tissue spaces. Enteral cleavage results in
the major products glucagon-like peptide 1 (GLP-1), glu-
cagon-like peptide 2 (GLP-2) and glicentin. Glicentin is
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cleaved to oxyntomodulin and glicentin-related pancre-
atic product (GRPP). Oxyntomodulin closely resembles
glucagon with the only difference being an eight amino
acid C-terminus extension [8]. The glucagon receptor has
only a 2% affinity for oxyntomodulin but does exhibit
some limited glucagon-like bioactivity [8]. GRPP is
formed in both pancreatic and intestinal tissues.
Enteroglucagon secreting tumors have been reported
but detection of enteroglucagon was indirect [2,9,10].
Stevens et al. specifically reported assay positivity for an
N-terminal reactive antibody measuring both pancreatic
and gut glucagon-like immunoreactivity with negative C-
terminal reactive antibody more specific for pancreatic
glucagon and demonstrating only a 2% cross-reactivity
with gut extracts [9]. These tumors were clinically diag-
nosed and treated as glucagonomas [2,9,10].
Case presentation
Our patient was a 64-year-old Caucasian man referred
from an outside hospital for evaluation and treatment of
obstructive jaundice secondary to a periampullary mass.
Patient informed consent for publication of findings was
obtained during admission. Prior admission to the outly-
ing hospital had occurred 5 days before transfer following
presentation with jaundice, fatigue and bilateral lower
extremity edema.
Hypoalbuminemia, refractory severe hypokalemia,
uncontrolled new onset diabetes mellitus, and anemia
were associated findings. New onset diabetes mellitus
was diagnosed 3 weeks before developing jaundice. His
medical history was significant for gout, hypertension,
hyperlipidemia, osteoarthritis, degenerative disk disease,
erectile dysfunction, and two episodes of idiopathic pan-
creatitis 15 years earlier. Glycosylated hemoglobin mea-
sured an elevated 7.5%. Endoscopic retrograde
cholangiopancreatography (ERCP) was performed at the
referring institution before transfer. Biopsies returned a
diagnosis of neuroendocrine tumor, not otherwise speci-
fied. The patient was then transferred to our hospital. His
serum potassium remained low despite all replacement
efforts. Hypoalbuminemia worsened to 1.6 gm/dL.
Serum glucagon was measured using Siemens' Double
Glucagon Antibody and found to be depressed (37 ng/L;
normal 40-130 ng/L). The serum serotonin level (< 25 ng/
mL) was low (normal 90-195 ng/L) and the vasoactive
intestinal polypeptide (VIP) level (< 30 pg/mL) was
within normal limits (normal < 100 ng/L). Carcinoem-
bryonic antigen (CEA) level was normal at 1.1 ng/mL.
Carbohydrate antigen 19-9 (CA 19-9) was markedly ele-
vated at 233.5 U/mL. Computed tomography revealed a
3.2 cm by 1.9 cm hypervascular mass in the medial duo-
denal wall juxtaposing the pancreas. Three hepatic
lesions appeared consistent with metastasis.
Exploratory laparotomy was performed. Five perihe-
patic lymph nodes appeared suspicious for metastatic
disease; they were surgically excised and examined by
frozen section. Three of these five lymph nodes were pos-
itive for metastatic neuroendocrine carcinoma. Two liver
masses each less than 1 cm were identified by intra-oper-
ative ultrasound. Each lesion was wedge resected and
pathologic examination confirmed metastases. Pancreati-
coduodenectomy was indicated and performed due to
lymph node and hepatic metastases. Pathology speci-
mens stained positive for chromogranin, synaptophysin,
and glucagon. The tumor mass was 4.5 cm and infiltrated
through the duodenal wall into the pancreas. Extensive
angiolymphatic invasion was noted.
The patient's post-operative course was complicated by
respiratory aspiration, disseminated candidiasis with can-
didal sepsis, wound infection, disseminated varicella,
atrial fibrillation, acute renal failure and a subhepatic
intra-abdominal candidal abscess. Discharge to a rehabil-
itation center occurred on post-operative day 53. Results
of the multidisciplinary gastrointestinal tumor board rec-
ommended close monitoring with long-acting octreotide.
Discussion
The patient presented clinically with evidence supporting
a glucagonoma. The classic glucagonoma syndrome con-
sists of necrotizing migratory erythema, hyperglycemia
without ketosis, weight loss, and anemia [1,4,11]. Uncon-
trolled new onset diabetes mellitus without ketosis, nor-
mochromic and normocytic anemia, and
hypoalbuminemia were recognized in this patient on
admission. Peripheral edema was present in our patient
and has been reported in association with glucagonomas
and enteroglucagonomas [9,10]. Tissue biopsy confirmed
a neuroendocrine tumor origin and the absence of an
associated tumor within the pancreas solidified a duode-
nal origin.
The Whipple resection specimen consisted of a seg-
ment of distal stomach, duodenum, and proximal pan-
creas. Located in the immediate periampullary region
was a 4.5 × 2.0 × 1.5 cm well-circumscribed solid firm
tan-yellow submucosal nodule covered by intact mucosa.
Light microscopy demonstrated the tumor infiltrating
through the duodenal wall into the superficial pancreas.
On immunohistochemistry, tumor cells were positive for
synaptophysin, chromogranin and glucagon. The manu-
facturer reported that the Polyclonal Rabbit Anti-Human
Glucagon antibody reacts with all moieties containing the
glucagon molecule (DakoCytomation, Inc.: Package Insert
and Laboratory Notes, Immunogen: Human Glucagon
(Polyclonal Rabbit Anti-Human Glucagon). Carpinteria,
California: DakoCytomation, Inc.) We sought to clarify
the inconsistencies in the serum and tissue glucagon
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The analyzing laboratory was contacted and no com-
promise of the patient's submitted specimen was sus-
pected. Prior studies performed by Siemens (Los Angeles,
CA, USA) showed that the Double Antibody Glucagon
I125  radioimmunoassay used for serum glucagon level
determination failed to detect any glucagon reactivity
with the addition of Glucagon-like Peptide 1 (GLP-1),
Glucagon-like Peptide 2 (GLP-2), or Oxyntomodulin
(Glucagon 37/Enteroglucagon) to a level of 1,000,000 pg/
ml (Siemens, Inc.: Package Insert, Double Antibody Gluca-
gon. Siemens Los Angeles, California). Sensitivity for
human pancreatic glucagon, however, was excellent. The
Siemens' Double Antibody Glucagon I 125 radioimmuno-
assay then has particular specificity for pancreatic gluca-
gon but not enteral glucagon. Consequently, analysis of
the patient's serum only indicated the level of pancreatic
glucagon while tissue reactivity with Polyclonal Rabbit
Anti-Human Glucagon reagent was capable of detecting
both pancreatic and enteral glucagon. To summarize, the
laboratory blood and solid tissue results revealed an
intestinal neuroendocrine tumor producing a non-pan-
creatic form of glucagon: enteroglucagon. GLP-1 inhibi-
tion of glucagon secretion may have resulted in the
depressed serum level of detectable pancreatic glucagon
[8].
Conclusion
Serum glucagon levels measured with Double Antibody
Glucagon  reflect only pancreatic glucagon production
and do not indicate enteroglucagon production. Tissue
analysis using Polyclonal Rabbit Anti-Human Glucagon
detects any glucagon sequence containing moieties
including enteroglucagon. Patients clinically exhibiting a
glucagonoma syndrome with paradoxical low serum glu-
cagon levels and tissue glucagon immunohistochemical
positivity may possess an underlying enteroglucagonoma.
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